APA (7th ed.) Citation

E, T., E, K., I, N., D, C., A, P., E, E., . . . MA, D. (2019). Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. American journal of hematology, 94(4), 400. https://doi.org/10.1002/ajh.25392

Chicago Style (17th ed.) Citation

E, Terpos, et al. "Consolidation Therapy with the Combination of Bortezomib and Lenalidomide (VR) Without Dexamethasone in Multiple Myeloma Patients After Transplant: Effects on Survival and Bone Outcomes in the Absence of Bisphosphonates." American Journal of Hematology 94, no. 4 (2019): 400. https://doi.org/10.1002/ajh.25392.

MLA (9th ed.) Citation

E, Terpos, et al. "Consolidation Therapy with the Combination of Bortezomib and Lenalidomide (VR) Without Dexamethasone in Multiple Myeloma Patients After Transplant: Effects on Survival and Bone Outcomes in the Absence of Bisphosphonates." American Journal of Hematology, vol. 94, no. 4, 2019, p. 400, https://doi.org/10.1002/ajh.25392.